First Dosing of Participant in the First Clinical Trial of Jiangsu Vcare's Highly Selective JAK1 Inhibitor VC005 Tablets
Published Time:
2021-11-22 17:43
Source:
On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.
About VC005
VC005 tablets is a novel, potent, and highly selective JAK1 inhibitor independently developed by Jiangsu Vcare. The drug selectively inhibits JAK1, thereby suppressing immune cell-mediated cytotoxicity and immune responses, while exhibiting weaker inhibitory activity against JAK2. VC005 tablets received clinical trial implied permission from the NMPA on August 31st, 2021, for the indication of inflammatory bowel disease (IBD).
About JAK1
The JAK-STAT pathway plays a crucial role in the pathogenesis of diseases such as IBD. Currently marketed oral JAK inhibitors, due to their low selectivity, inhibit JAK1 while also affecting targets like JAK2 and JAK3. This has resulted in significant adverse reactions in clinical settings, including anemia, infections, dyslipidemia, and malignancies, leading to FDA boxed warnings. Since the first half of 2021, the FDA has repeatedly delayed review decisions for pan-JAK inhibitor drugs, drawing intense attention from the biopharmaceutical industry. Consequently, the development of highly selective JAK1 inhibitors has become an key trend. Notably, no JAK inhibitors are currently approved in China for IBD, highlighting a critical unmet clinical need.
VC005's development strategy is rooted in differentiation, specifically addressing the aforementioned issues from the project initiation and design stages. Preclinical studies have confirmed that compared to drugs targeting the same pathway, VC005 demonstrates a lower effective dose, higher tolerated dose, and fewer side effects in animal models, suggesting potential dual advantages in both safety and efficacy. It holds promise to become a globally leading therapeutic option for autoimmune and inflammatory diseases.
About IBD
IBD is a group of non-specific, chronic inflammatory intestinal disorders, primarily classified clinically as ulcerative colitis (UC) and Crohn's disease (CD). Key manifestations include abdominal pain/diarrhea, bloody stool, and weight loss, characterized by being difficult to cure, prone to relapse, and carrying a potential risk of malignant transformation. Epidemiologically, there are significant regional disparities globally. Western countries are in a compounded epidemic phase, with an incidence rate of 12-16 per 100,000 population. China is currently in an accelerating phase of the disease; owing to its large population base, the total number of cases reached 350,000 between 2005 and 2014, and is projected to reach 1.5 million by 2025, indicating a rapidly increasing prevalence. Regarding therapeutic drugs, small-molecule JAK inhibitors, unlike biologics, are non-immunogenic. This characteristic enables them to effectively avoid secondary failure caused by neutralizing antibodies in humans.
Previous Page
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn